Acute Candesartan Cilexetil Evaluation in Stroke Survivors "ACCESS"

Completed

Phase N/A Results

Results

Combined endpoint of total mortality, cerebral complications and cardiovascular complications, was reduced by 47.5 percent for patients treated with Atacand (4-16 mg) initiated within 72 hrs post stroke.